Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.

MLA

Pan, Edward, et al. “Phase I Study of RO4929097 with Bevacizumab in Patients with Recurrent Malignant Glioma.” Journal of Neuro-Oncology, vol. 130, no. 3, Dec. 2016, pp. 571–79. EBSCOhost, https://doi.org/10.1007/s11060-016-2263-1.

APA

Pan, E., Supko, J. G., Kaley, T. J., Butowski, N. A., Cloughesy, T., Jung, J., Desideri, S., Grossman, S., Ye, X., & Park, D. M. (2016). Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. Journal of Neuro-Oncology, 130(3), 571–579. https://doi.org/10.1007/s11060-016-2263-1

Chicago

Pan, Edward, Jeffrey G Supko, Thomas J Kaley, Nicholas A Butowski, Timothy Cloughesy, Jinkyu Jung, Serena Desideri, Stuart Grossman, Xiaobu Ye, and Deric M Park. 2016. “Phase I Study of RO4929097 with Bevacizumab in Patients with Recurrent Malignant Glioma.” Journal of Neuro-Oncology 130 (3): 571–79. doi:10.1007/s11060-016-2263-1.